Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MASTER: KRdD Sequential Therapy in Multiple Myeloma
NCT03224507Phase 2Completed
- Sponsor
- University of Alabama at Birmingham
- Start
- Mar 2018
- Primary completion
- May 2023
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of daratumumab in multiple myeloma (MM), sponsored by University of Alabama at Birmingham. Started Mar 2018; status: completed.
02
Drugs
daratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03224507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03224507.